Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avastin Fails First-Line Pancreatic Cancer Trial, But Pancreatic Program Will Continue

This article was originally published in The Pink Sheet Daily

Executive Summary

Genentech and partner Roche await results from another first-line pancreatic cancer trial, AVITA, with enrollment slated to complete by year-end.

You may also be interested in...



Avastin Added To Tarceva/Gemcitabine Fails To Prolong Survival In Phase III Pancreatic Cancer Trial

Roche-sponsored trial did not meet the primary endpoint of overall survival, but did show some clinical benefits.

Avastin Added To Tarceva/Gemcitabine Fails To Prolong Survival In Phase III Pancreatic Cancer Trial

Roche-sponsored trial did not meet the primary endpoint of overall survival, but did show some clinical benefits.

Sanofi Positioning Aflibercept To Compete With Genentech’s Avastin In Certain Settings

Company plans to file VEGF Trap for its first indication, ovarian cancer, in 2008, followed by second-line lung cancer and second-line colorectal cancer.

Related Content

Topics

UsernamePublicRestriction

Register

ID020288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel